Biopharma company argenx has secured multiple commendations from the European Commission (EC) and The U.S. Food and Drug Administration (FDA) for their drug VYVGART and its subcutaneous injections designed to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disease. These approvals extend argenx's foothold in the autoimmune disorder market further. Additionally, argenx is involved in a health marketing collaboration with NBC. argenx plans to treat 50,000 patients with ten labeled indications by 2025. The FDA has also approved the syringe version of argenx's immune disorder drug. Despite promising sales, argenx's stock has experienced some fluctuations. Analysts from Wedbush and Baird have reiterated 'Outperform' and 'Buy' ratings respectively. argenx has reported their first quarter 2025 financial results, which were greeted with enthusiasm as promising growth prospects of VYVGART drive a 'Buy' rating sentiment. Future presentations at major healthcare conferences promise to shed more light on the strategic direction of the company.
argenx News Analytics from Tue, 15 Oct 2024 07:00:00 GMT to Thu, 26 Jun 2025 16:21:36 GMT - Rating 8 - Innovation 9 - Information 7 - Rumor 5
